Enalare Therapeutics Inc. news
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose.
Enalare Therapeutics Inc., a biopharmaceutical company dedicated
The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States
Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to deve
- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity
- Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter
- ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the neck. By inhibiting these channels, ENA-001 utilizes the body’s own ventilation control system to stimulat
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). Funding from the grant will be used to further the development of ENA001, Enalare`s unique agnostic respiratory stimulant for the treatment of respiratory depression due to opioi
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has completed a propofol induced respiratory depression study with its lead compound ENA001, having achieved the targeted primary endpoint. The objective of the study was to demonstrate the ability of ENA001 to reverse respiratory depression induced through administration of propofol, a central nervous sys